Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Recruiting
Observational Study
Advanced ALK/ROS1-positive NSCLC
Carcinoma, Non-Small-Cell Lung (NSCLC)
Lung Adenocarcinoma
ALK-positive Non-small Cell Lung Cancer (NSCLC)
Cognitive Dysfunction
Depression
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 24 (estimated)
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients with non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements.
Lorlatinib is a highly effective third-generation tyrosine kinase inhibitor, but it cau…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed diagnosis of ALK/ROS1-positive non-small cell lung cancer (NSCLC), stage IIIB/IV.
* Currently receiving lorlatinib as part of the standard therapeutic regimen.
* Documented neurocognitive adverse events (NAEs) attributable to lorlatinib.
* Age \>= 18 y…
Contacts